A.I. BURNASYAN FMBC CLINICAL BULLETIN

ISSN 2782-6430 (print)

State Research Center −Burnasyan Federal Medical Biophysical
Center of Federal Medical Biological Agency

The journal is published in Russian.
Format – A4.
The periodicity of the journal is 4 times a year.

Issue №2 2025 год

more

A.I. Burnasyan  FMBC clinical bulletin. 2023 № 4

V.V. Borodulin, I.V. Sidyakina, I.V. Podenok, V.F. Kazakov

The Role of Biochemical Markers in the Diagnosis and Rehabilitation of Patients with Acute Cerebral Ischemia: Literature Review

International Office, State Research Center – Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency, Moscow, Russiа

Contact person: Podenok Ivan Vladimirovich: ivanpodenok@mail.ru


Abstract
Purpose: The purpose of this literature review was to conduct a meta-analysis on the use of biochemical markers in the diagnosis and rehabilitation of patients with acute cerebral ischemia. eLibrary, Web of Science, Scopus, Medline resources were used to search for materials from 1995 to 2022. The terms of inclusion in the search criteria were “biochemical markers”, “cerebral ischemia”, “acute cerebrovascular accident”, “ischemic stroke”, “rehabilitation”. As a result of the search, 62 articles were found. Studies show that the role of biochemical markers in the diagnosis of patients with acute cerebral ischemia is extremely high. One of the promising markers is the level of NR2 antibodies to NMDA glutamate receptors. The conducted studies have generally shown that the level of NR2 antibodies to NMDA glutamate receptors can be used to diagnose ischemic stroke, monitor the course of the disease in dynamics, predict outcomes and personalize therapeutic approaches. It seems promising to further study this biomarker in the context of personalization of rehabilitation programs for patients.

Keywords: biochemical markers, ischemic stroke, rehabilitation

For citation: Borodulin VV, Sidyakina IV, Podenok IV, Kazakov VF. The Role of Biochemical Markers in the Diagnosis and Rehabilitation of Patients with Acute Cerebral Ischemia: Literature Review. A.I. Burnasyan Federal Medical Biophysical Center Clinical Bulletin. 2023.4:35-42. (In Russian) DOI: 10.33266/2782-6430-2023-4-35-42


REFERENCES

  1. Katan M., Luft A. Global Burden of Stroke. Semin Neurol. 2018;38(2):208-211.
  2. Kim J., Thayabaranathan T., Donnan G.A. et al. Global Stroke Statistics 2019. Int J Stroke. 2020;15(8):819-838.
  3. Saini V., Guada L., Yavagal D.R. Global Epidemiology of Stroke and Access to Acute Ischemic Stroke Interventions. Neurology. 2021;97(20 Suppl 2):S6-S16.
  4. Thayabaranathan T., Kim J., Cadilhac D.A. et al. Global stroke statistics 2022. Int J Stroke. 2022;17(9):946-956.
  5. Roth G.A., Mensah G.A., Johnson C.O. et al. ,; GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020;76(25):2982-3021.
  6. 6. Dambinova S. A., Skoromets A.A., Skoromets A.P. Biomarkers of cerebral ischemia (development, research and practice). St. Petersburg: Costa, 2013. – 336 p
  7. . 7. Ponomarev G.V., Polyakova A.V., Prokhorova M.V., Voznyuk I.A. Biomarkers of stroke: issues of diagnosis and medical rehabilitation. Physical and rehabilitation medicine, medical rehabilitation. 2022; 4(4): 259-270.
  8. 8. Skoromets A.A., Dambinova S.A., Diakonov M.M., etc. New biomarkers of brain lesions. Neuroimmunology 2009; 7(2): 18-23.
  9. Dias A., Silva L., Moura J. et al. Fluid biomarkers in stroke: From animal models to clinical care. Acta Neurol Scand. 2022;146(4):332-347.
  10. Foschi M., Padroni M., Abu-Rumeileh S. et al. Diagnostic and Prognostic Blood Biomarkers in Transient Ischemic Attack and Minor Ischemic Stroke: An Up-To-Date Narrative Review. J Stroke Cerebrovasc Dis. 2022;31(3):106292.
  11. Kamtchum-Tatuene J., Jickling G.C. Blood Biomarkers for Stroke Diagnosis and Management. Neuromolecular Med. 2019;21(4):344-368.
  12. Mosconi M.G., Paciaroni M. Treatments in Ischemic Stroke: Current and Future. Eur Neurol. 2022;85(5):349-366.
  13. Stakhovskaya L.V., Klochikhina O.A., Bogatyreva M.D., Chugunova S.A. Analysis of epidemiological indicators of recurrent strokes in the regions of the Russian Federation (based on the results of the territorial population register 2009-2014). Consilium Medicum. 2016; 18 (9): 8-11.го регистра 2009–2014 гг.). Consilium Medicum. 2016; 18 (9): 8-11.
  14. Gusev E.I., Skvortsova V.I. Cerebral ischemia, M.: Medicine, 2001, 328 p.
  15. . Chukanova A.S., Chukanova E.I., Nadareishvili G.G., Gulieva M.Sh., Gusev E.I. Pathogenetic aspects of the formation of acute focal cerebral ischemia. Journal of Neurology and Psychiatry named after S.S. Korsakov. Special issues. 2017;117(12 2):4 10.
  16. Kogure T., Kogure K. Molecular and biochemical events within the brain subjected to cerebral ischemia (targets for therapeutical intervention). Clin Neurosci. 1997;4(4):179–183.
  17. Lipton P. Ischemic cell death in brain neurons. Physiol Rev. 1999;79:1431- 1568
  18. Obrenovitch T.P. The ischaemic penumbra: twenty years on. Cerebrovasc Brain Metab Rev. 1995;7:297-323.
  19. Lai TW, Zhang S, Wang YT. Excitotoxicity and stroke: identifying novel targets for neuroprotection. Prog Neurobiol. 2014;115:157-188.
  20. Meldrum B.S. Glutamate as a neurotransmitter in the brain: review of physiology and pathology. J Nutr. 2000;130(4S):1007S 1015S.
  21. Platt S.R. The role of glutamate in central nervous system health and disease — a review. Vet J. 2007;173(2):278–286.
  22. Wang Y., Qin Z.H. Molecular and cellular mechanisms of excitotoxic neuronal death. Apoptosis. 2010;15(11):1382–1402.
  23. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001; 69(3): 89—95
  24. Dancey J.E., Dobbin K.K., Groshen S. et al. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin. Cancer Res. 2010; 16(6): 1745—55.
  25. Hess S., Ozoux M.L., Gerl M. Biomarker Definition and Validation During Drug Development. Berlin: Springer; 2011: 223—44.
  26. Kumar M., Sarin S.K. Biomarkers of diseases in medicine. Current Trends in Science. Platinum Jubilee Special. 2009: 403-417.
  27. Poste G. Bring on the biomarkers. Nature. 2011; 469(7329): 156—7.
  28. Lynch J.R., Blessing R., White W.D. et al. Novel diagnostic test for acute stroke. Stroke. 2004; 35(1): 57–63.
  29. Stamova B., Xu H., Jickling G. et al. Gene expression profiling of blood for the prediction of ischemic stroke. Stroke. 2010; 41(10): 2171–2177.
  30. Park K.Y., Ay I., Avery R. et al. New biomarker for acute ischaemic stroke: plasma glycogen phosphorylase isoenzyme BB. J Neurol Neurosurg Psychiatry. 2018;89(4):404-409.
  31. Bustamante A., Lopez-Cancio E., Pich S. et al. Blood Biomarkers for the Early Diagnosis of Stroke: The Stroke-Chip Study. Stroke. 2017; 48(9): 2419–2425.
  32. Abdelhak A., Foschi M., Abu-Rumeileh S. et al. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol. 2022;18(3):158-172.
  33. Foerch C., Niessner M., Back T. et al. Diagnostic accuracy of plasma glial fibrillary acidic protein for differentiating intracerebral hemorrhage and cerebral ischemia in patients with symptoms of acute stroke. Clin Chem. 2012; 58(1): 237–245.
  34. Luger S., Witsch J., Dietz A. et al. Glial Fibrillary Acidic Protein Serum Levels Distinguish between Intracerebral Hemorrhage and Cerebral Ischemia in the Early Phase of Stroke. Clin Chem. 2017; 63(1): 377–385.
  35. Perry L.A., Lucarelli T., Penny-Dimri J.C. et al. Glial fibrillary acidic protein for the early diagnosis of intracerebral hemorrhage: Systematic review and meta-analysis of diagnostic test accuracy. Int J Stroke. 2018; 1747493018806167
  36. Katan M., Fluri F., Schuetz P. et al. Midregional pro-atrial natriuretic peptide and outcome in patients with acute ischemic stroke. J Am Coll Cardiol. 2010; 56(13): 1045–1053.
  37. Bai J., Sun H., Xie L. et al. Detection of cardioembolic stroke with B-type natriuretic peptide or N-terminal pro-BNP: a comparative diagnostic meta-analysis. Int J Neurosci. 2018;128(11):1100-1108.
  38. Zhu Z., Tang W., Ge L. et al. The value of plasma fibrillin-1 level in patients with spontaneous cerebral artery dissection. Neurology. 2018;90(9):e732-e737.
  39. Tiedt S., Duering M., Barro C. et al. Serum neurofilament light a biomarker of neuroaxonal injury after ischemic stroke. Neurology. 2018;91:E1338-E1347.
  40. Purroy F., Farré-Rodriguez J., Mauri-Capdevila G. et al. Basal IL-6 and S100b levels are associated with infarct volume. Acta Neurol Scand. 2021;144:517-523.
  41. Chen C.H., Chu H.J., Hwang Y.T. et al. Plasma neurofilament light chain level predicts outcomes in stroke patients receiving endovascular thrombectomy. J Neuroinflammation. 2021;18:1-12.
  42. Luger S., Koerbel K., Martinez Oeckel A. et al. Role of s100b serum concentration as a surrogate outcome parameter after mechanical thrombectomy. Neurology. 2021;97:E2185-E2194.
  43. Voznyuk I.A., Pivovarova L.P., Gogoleva E.A. and others. Biomarkers of brain damage and inflammation in patients with acute cerebral ischemia. Journal of Neurology and Psychiatry named after S.S. Korsakov. Special issues. 2022;122(8 2):54 60.
  44. Voznyuk I.A., Ponomarev G.V., Kharitonova T.V., etc. Diagnostic features of the level of antibodies to NR2-peptide in patients with chronic cerebral ischemia. Annals of Clinical and Experimental Neurology 2021; 15(2):5-12.
  45. Ponomarev G.V., Voznyuk I.A., Izumi M.A., Skoromets A.A. Glutamate biomarkers in the complex diagnosis of acute and chronic cerebral ischemia. Annals of Clinical and Experimental Neurology 2020; 14(4): 15-22.
  46. Dambinova S.A., Bettermann K., Glynn T. et al. Diagnostic potential of the NMDA receptor peptide assay for acute ischemic stroke. PLoS One. 2012;7(7): e42362.
  47. Rosenmund C., Stern-Bach Y., Stevens C.F. The tetrameric structure of a glutamate receptor channel. Science. 1998;280 (5369):1596–1599.
  48. Bokesch P.M., Izykenova G.A., Justice J.B. et al. NMDA receptor antibodies predict adverse neurological outcome after cardiac surgery in high-risk patients. Stroke. 2006; 37(6): 1432–1436.
  49. Gascon S., Sobrado M., Roda J.M. et al. Excitotoxicity and focal cerebral ischemia induce truncation of the NR2A and NR2B subunits of the NMDA receptor and cleavage of the scaffolding protein PSD 95. Mol Psychiatry. 2008;13(1):99–114.
  50. Platt S.R. The role of glutamate in central nervous system health and disease — a review. Vet J. 2007;173(2):278–286.
  51. Dambinova S.A., Khounteev G.A., Izykenova G.A. et al. Blood test detecting autoantibodies to N-methyl-D-aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke. Clin Chem. 2003; 49(10): 1752–1762.
  52. Dambinova S.A., Khounteev G.A., Skoromets A.A. Multiple panel of biomarkers for TIA/stroke evaluation. Stroke. 2002;33(5):1181–1182.
  53. Stanca D.M., Mărginean I.C., Soriău O. et al. GFAP and antibodies against NMDA receptor subunit NR2 as biomarkers for acute cerebrovascular diseases. J Cell Mol Med. 2015;19(9):2253–2261
  54. Weissman J.D., Khunteev G.A., Heath R., Dambinova S.A. NR2 antibodies: risk assessment of transient ischemic attack (TIA)/stroke in patients with history of isolated and multiple cerebrovascular events. J Neurol Sci. 2011;300(1–2):97–102.
  55. Klimenko L.L., Skalny A.V., Turna A.A. et al. Serum trace element profiles, prolactin, and cortisol in transient ischemic attack patients. Biol Trace Elem Res. 2016;172(1):93–100.
  56. Ponomarev G.V., Lalayan T.V., Dambinova S.A., Skoromets A.A. Biomarkers of neurotoxicity as potential indicators of spinal cord ischemia. Journal of Neurology and Psychiatry named after S.S. Korsakov. 2018;118(2):52 57.
  57. Ochkolyas V.N., Sokurenko G.Yu. Assessment of the severity of cerebral ischemia after surgical treatment of internal carotid artery pathology by determining the level of autoantibodies to the NR2A subunit of NMDA glutamate receptors. Surgery news. 2014; 22(2): 171-178.
  58. Khunteev G.A., Zavolokov I.G., Cherkas Yu.V., Dambinova S.A. The practical significance of determining the level of antibodies to NMDA-type glutamate receptors in the diagnosis of disorders of cerebral circulation. Journal of Neurology and Psychiatry named after S.S. Korsakov 2001; 101(11): 44-47.
  59. Granstrom O.K., Dambinova S.A., Diakonov M.M., etc. Dynamics of biomarkers of brain ischemia in dyscirculatory encephalopathy on the background of cortexin treatment. Medline Express 2009; 4-5(203): 29-33.
  60. Smolko D.G. The level of antibodies to NMDA receptors in patients with chronic cerebral circulatory insufficiency. International Journal of Neurology 2016; 3(81): 66-68.
  61. González-García S., González-Quevedo A., Hernandez-Diaz Z., et al. Circulating Autoantibodies Against the NR2 Peptide of the NMDA Receptor are Associated with Subclinical Brain Damage in Hypertensive Patients with other Pre-Existing Conditions for Vascular Risk. J. Neurol. Sci. 2017;375:324–330.
  62. Dambinova S.A., Aliyev K.T., Bondarenko E.V., et.al. The Biomarkers of Cerebral Ischemia as a New Method for the Validation of the Efficacy of Cytoprotective Therapy. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117;5:62–67 (In Russ.).

 

Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 15.09.2023.  Accepted for publication: 16.10.2023        

© 2025 Scientific journal - "Clinical Bulletin of the FMBС im. A.I. Burnasyan"
Scroll to Top